Gary Fishman, MD
Otolaryngology · Daytona Beach, FLNPI 1831138304
Payments from drug & device makers
Across 106 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$688
- Sanofi$426
- Regeneron Healthcare Solutions, Inc.$416
- Intersect ENT, Inc.$136
- Medtronic$128
- Boston Scientific$119
- plus $580 from 16 others
What the payments were for
- Food & beverage$2,493100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $688 |
| Sanofi | 14 | $426 |
| Regeneron Healthcare Solutions, Inc. | 17 | $416 |
| Intersect ENT, Inc. | 3 | $136 |
| Medtronic(2 entities) | 7 | $128 |
| Boston Scientific | 2 | $119 |
| Optinose US, Inc. | 4 | $79 |
| Kaleo, Inc. | 4 | $74 |
| Pfizer | 5 | $71 |
| Alk-abello, Inc | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Neurent Medical Limited | 3 | $44 |
| Novartis | 2 | $41 |
| AstraZeneca | 2 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Glenmark Therapeutics Inc. | 1 | $15 |
| Aerin Medical Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$2,493 in reported general payments places this provider in the 60th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 171 | $9,824 |
| Ipratropium Bromide | 217 | $5,568 |
| Famotidine | 436 | $4,917 |
| Omeprazole | 357 | $4,158 |
| Fluticasone Propionate | 269 | $3,782 |
| Cefdinir | 201 | $3,605 |
| Azelastine Hcl | 70 | $1,565 |
| Methylprednisolone | 229 | $1,486 |
| Ofloxacin | 20 | $565 |
| Azithromycin | 51 | $166 |
| Prednisone | 26 | $122 |
| Pantoprazole Sodium | 16 | $105 |
| Meclizine Hcl | 15 | $53 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Daytona Beach
- Craig ShapiroHollywood$8.1M
- Adrien EshraghiMiami$2.1M
- Cecelia DamaskOrlando$771K
- Ralph TufanoSarasota$733K
- Mitchell MillerClearwater$709K
- Brian KerrGainesville$629K
- Maria SuurnaMiami$456K
- Mark TaborTampa$348K
- Franklin RimellFort Myers$314K
- Tapan PadhyaTampa$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.